{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:33:22Z","timestamp":1786653202061,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/1008-682x.174856","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T01:44:16Z","timestamp":1453686256000},"page":"178","source":"Crossref","is-referenced-by-count":23,"title":["Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients"],"prefix":"10.4103","volume":"19","author":[{"given":"Bo","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Wei","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.174856-1","first-page":"238","volume-title":"Androgen deprivation therapy for prostate cancer","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"key-10.4103\/1008-682X.174856-2","first-page":"333","volume-title":"Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series","author":"Morrissey","year":"2013","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/1008-682X.174856-3","first-page":"104","volume-title":"Prostate cancer therapy: going forwards by going backwards","author":"Sweeney","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.174856-4","first-page":"881, 3","volume-title":"In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel.No, not yet?","author":"Armstrong","year":"2014","journal-title":"Oncology"},{"key":"key-10.4103\/1008-682X.174856-5","first-page":"880, 2","volume-title":"In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel.Yes; we must beware of drawing conclusions from a subset analysis?","author":"Suzman","year":"2014","journal-title":"Oncology"},{"key":"key-10.4103\/1008-682X.174856-6","first-page":"149","volume-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.174856-7","first-page":"572","volume-title":"EAU guidelines on prostate cancer.Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.174856-8","first-page":"119","volume-title":"Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy","author":"Morote","year":"2005","journal-title":"Int J Biol Markers"},{"key":"key-10.4103\/1008-682X.174856-9","first-page":"648","volume-title":"Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?","author":"Perachino","year":"2010","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.174856-10","first-page":"481","volume-title":"Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk","author":"Morote","year":"2010","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.174856-11","first-page":"65","volume-title":"Testosterone measurement in patients with prostate cancer","author":"Schulman","year":"2010","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.174856-12","doi-asserted-by":"publisher","unstructured":"Bertaglia V, Tucci M, Fiori C, Aroasio E, Poggio M, et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013; 11: 325-30.e1.","DOI":"10.1016\/j.clgc.2013.01.002"},{"key":"key-10.4103\/1008-682X.174856-13","first-page":"235","volume-title":"Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis","author":"Shariat","year":"2008","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/1008-682X.174856-14","doi-asserted-by":"publisher","unstructured":"Morote J, Planas J, Salvador C, Raventos CX, Catalan R, et al. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU int 2009; 103: 332-5. [Discussion 5].","DOI":"10.1111\/j.1464-410X.2008.08062.x"},{"key":"key-10.4103\/1008-682X.174856-15","first-page":"1290","volume-title":"Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy","author":"Morote","year":"2007","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.174856-16","first-page":"6407","volume-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.174856-17","doi-asserted-by":"publisher","unstructured":"Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49: 54-8. [Discussion 8].","DOI":"10.1016\/j.eururo.2005.09.009"},{"key":"key-10.4103\/1008-682X.174856-18","first-page":"2448","volume-title":"Gender differences in the ST segment: effect of androgen-deprivation therapy and possible role of testosterone","author":"Ezaki","year":"2010","journal-title":"Circ J"},{"key":"key-10.4103\/1008-682X.174856-19","first-page":"173","volume-title":"Dehydroepiandrostenedione sulphate interferes in many direct immunoassays for testosterone","author":"Middle","year":"2007","journal-title":"Ann Clin Biochem"},{"key":"key-10.4103\/1008-682X.174856-20","first-page":"737","volume-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.174856-21","first-page":"1039","volume-title":"Observed advantages of the STAMPEDE study design","author":"Scher","year":"2015","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.174856-22","first-page":"837","volume-title":"Androgen deprivation therapy in prostate cancer: looking beyond prostate-specific antigen and testosterone levels","author":"Saad","year":"2014","journal-title":"Eur Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:33:23Z","timestamp":1786649603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1008-682X.174856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"alternative-id":["174856"],"URL":"https:\/\/doi.org\/10.4103\/1008-682x.174856","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}